Comparison tool

Thyreogen vs Livagen side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

ThyreogenLivagen

Share this peptide comparison

Property	Thyreogen	Livagen
Category	Bioregulators	Bioregulators
Also known as	-	Lys-Glu-Asp-Ala, KEDA
FDA approved	No	No
Clinical status	Preclinical research; approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research; reported as approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Thyroid function, metabolism, thyroid health	Gene expression, cellular aging, liver health
How it works	Thyreogen is described under the Khavinson bioregulator framework. In that model, short tissue-derived peptides are hypothesized to enter cells and influence gene-expression programs, potentially through DNA-associated effects. The source reports thyroid-focused vendor claims involving thyroid-cell metabolism and T3, T4, and calcitonin output, but it also states that a Thyreogen-specific receptor, pathway, or independently established mechanism has not been mapped.	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.
Typical dosing	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual
Research dosing	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typical duration	10-30 day cycles	10-30 day cycles
Administration	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Evidence level	Preclinical	Preclinical
Possible side effects	Generally well tolerated (Reported by the source; detailed safety data are limited.) May affect thyroid hormone levels (Source-reported safety consideration.) Limited safety data outside Russia (Evidence base may not generalize broadly.) +1 more Not FDA approved (Regulatory status note, not a physiological side effect.)	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)
Research summary	The source places Thyreogen within the broader Khavinson peptide bioregulator literature, which includes Russian publications and review-level discussions of short peptides as possible epigenetic regulators. It also states that evidence directly testing Thyreogen as a specific product is sparse, with no registered randomized placebo-controlled human trials for thyroid disease identified in the source material. Reported animal or family-level endocrine and geroprotective findings should therefore be treated as hypothesis-generating rather than proof for Thyreogen itself.	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.
References	PubMed PubMed Central +1 more SpringerLink	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Thyreogen

Livagen

Category

Bioregulators

Also known as

Lys-Glu-Asp-Ala, KEDA

FDA approved

Clinical status

Preclinical research; approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research; reported as approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Thyroid function, metabolism, thyroid health

Gene expression, cellular aging, liver health

How it works

Thyreogen is described under the Khavinson bioregulator framework. In that model, short tissue-derived peptides are hypothesized to enter cells and influence gene-expression programs, potentially through DNA-associated effects. The source reports thyroid-focused vendor claims involving thyroid-cell metabolism and T3, T4, and calcitonin output, but it also states that a Thyreogen-specific receptor, pathway, or independently established mechanism has not been mapped.

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Typical dosing

10-20 mg daily · Once or twice daily

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

Research dosing

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typical duration

10-30 day cycles

Administration

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Evidence level

Preclinical

Possible side effects

Generally well tolerated (Reported by the source; detailed safety data are limited.)
May affect thyroid hormone levels (Source-reported safety consideration.)
Limited safety data outside Russia (Evidence base may not generalize broadly.)

+1 more

Not FDA approved (Regulatory status note, not a physiological side effect.)

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Research summary

The source places Thyreogen within the broader Khavinson peptide bioregulator literature, which includes Russian publications and review-level discussions of short peptides as possible epigenetic regulators. It also states that evidence directly testing Thyreogen as a specific product is sparse, with no registered randomized placebo-controlled human trials for thyroid disease identified in the source material. Reported animal or family-level endocrine and geroprotective findings should therefore be treated as hypothesis-generating rather than proof for Thyreogen itself.

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

References

PubMed PubMed Central

+1 more

+2 more

Full profile